Torsten Pietsch

Torsten Pietsch's AcademicInfluence.com Rankings

Torsten Pietsch

Computer Science

#6342

World Rank

#6689

Historical Rank

Machine Learning

#2025

World Rank

#2051

Historical Rank

Artificial Intelligence

#2278

World Rank

#2317

Historical Rank

Database

#3440

World Rank

#3585

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Why Is Torsten Pietsch Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Torsten Pietsch's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

DNA methylation-based classification of central nervous system tumours (2018) (1461)
Negative Feedback Loop of Wnt Signaling through Upregulation of Conductin/Axin2 in Colorectal and Liver Tumors (2002) (1082)
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas (2012) (855)
EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME: IDENTIFICATION OF AND ADJUSTMENT FOR BIAS (2008) (836)
Long-term survival with glioblastoma multiforme. (2007) (812)
Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. (2015) (782)
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. (2009) (779)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. (2014) (744)
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas (2010) (714)
Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features (2008) (682)
New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs (2016) (608)
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. (2009) (561)
Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. (2005) (515)
International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading (2014) (514)
Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma (2014) (496)
NeuN: a useful neuronal marker for diagnostic histopathology. (1996) (482)
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. (2010) (476)
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. (2008) (456)
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus (2016) (406)
Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. (1997) (397)
Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. (2016) (374)
Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing (2014) (362)
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. (2013) (362)
Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate (2006) (351)
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. (2010) (338)
cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading (2020) (293)
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial (2019) (275)
Divergent clonal selection dominates medulloblastoma at recurrence (2016) (266)
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas (2011) (264)
Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. (2010) (251)
Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. (2012) (247)
Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups (2015) (245)
Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. (2001) (236)
Predictive impact of MGMT promoter methylation in glioblastoma of the elderly (2012) (234)
Deletion of Trp‐557 and Lys‐558 in the juxtamembrane domain of the c‐kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors (2003) (230)
Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays (2013) (230)
Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts (2011) (216)
Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. (2007) (213)
Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. (1999) (212)
Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. (2007) (209)
Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. (1999) (206)
Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up. (2011) (202)
Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. (2012) (201)
Betulinic acid: A new cytotoxic agent against malignant brain‐tumor cells (1999) (201)
Expression and distribution of vascular endothelial growth factor protein in human brain tumors (1997) (186)
Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. (2018) (184)
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. (2015) (183)
Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma (2014) (180)
Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91. (2009) (174)
C‐MYC expression in medulloblastoma and its prognostic value (2000) (173)
Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic? (2011) (171)
Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors (2001) (165)
Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity (2013) (165)
Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. (2016) (165)
Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. (2004) (163)
Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location (2018) (159)
The CD34 epitope is expressed in neoplastic and malformative lesions associated with chronic, focal epilepsies (1999) (159)
Combined postoperative irradiation and chemotherapy for anaplastic ependymomas in childhood: results of the German prospective trials HIT 88/89 and HIT 91. (2000) (157)
A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. (2015) (157)
Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations (2013) (152)
Elevated Expression of Wnt Antagonists Is a Common Event in Hepatoblastomas (2005) (148)
Phosphatidylinositol 3′-Kinase/AKT Signaling Is Activated in Medulloblastoma Cell Proliferation and Is Associated with Reduced Expression of PTEN (2006) (147)
Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. (2011) (146)
Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. (2009) (144)
Overexpression of Human Dickkopf-1, an Antagonist of wingless/WNT Signaling, in Human Hepatoblastomas and Wilms’ Tumors (2003) (142)
Effects of human stem cell factor (c-kit ligand) on proliferation of myeloid leukemia cells: heterogeneity in response and synergy with other hematopoietic growth factors. (1992) (141)
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. (2016) (140)
Activation of the CD95 (APO-1/Fas) pathway in drug- and γ-irradiation-induced apoptosis of brain tumor cells (1998) (136)
Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components (2006) (136)
Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial (2018) (131)
Anticancer Effects of Niclosamide in Human Glioblastoma (2013) (130)
Combined 1p/19q Loss in Oligodendroglial Tumors: Predictive or Prognostic Biomarker? (2007) (130)
Increased serum levels of granulocyte colony-stimulating factor in patients with severe congenital neutropenia. (1991) (129)
Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes (2010) (128)
Perilesional neurochemical changes in focal epilepsies (1996) (127)
Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo (2013) (124)
Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort (2014) (120)
Insulin-like growth factor II is involved in the proliferation control of medulloblastoma and its cerebellar precursor cells. (2005) (120)
Intensive chemotherapy improves survival in pediatric high‐grade glioma after gross total resection: results of the HIT‐GBM‐C protocol (2010) (120)
Surgery for Spinal Cord Ependymomas: Outcome and Prognostic Factors (2011) (120)
Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. (2015) (119)
Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91. (2002) (118)
Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC (2002) (118)
Beta‐catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E‐cadherin and accumulation of p53, but not with expression of conventional WNT‐1 target genes (2003) (118)
Frequency, Risk‐Factors and Survival of Children With Atypical Teratoid Rhabdoid Tumors (AT/RT) of the CNS Diagnosed between 1988 and 2004, and Registered to the German HIT Database (2011) (118)
Molecular characterization of long‐term survivors of glioblastoma using genome‐ and transcriptome‐wide profiling (2014) (117)
Medulloblastoma Variants: Age-Dependent Occurrence and Relation to Gorlin Syndrome—A New Clinical Perspective (2009) (116)
Amplification and overexpression of the IGF2 regulator PLAG1 in hepatoblastoma (2004) (115)
Residual tumor cells are unique cellular targets in glioblastoma (2010) (115)
Outcome of patients with intracranial non-germinomatous germ cell tumors—lessons from the SIOP-CNS-GCT-96 trial (2017) (115)
Infant high grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. (2020) (115)
Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors (2017) (114)
H3F3A K27M mutation in pediatric CNS tumors: a marker for diffuse high-grade astrocytomas. (2013) (113)
Loss of maternal alleles on chromosome arm 11p in hepatoblastoma. (1994) (112)
c-kit Mutations in Gastrointestinal Stromal Tumors Occur Preferentially in the Spindle Rather Than in the Epithelioid Cell Variant (2002) (112)
Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations? (2006) (109)
Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group (2013) (109)
Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis. (1999) (107)
Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas (2014) (106)
Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas. (2012) (102)
Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters. (2016) (102)
Prognostic Relevance of Clinical and Biological Risk Factors in Childhood Medulloblastoma: Results of Patients Treated in the Prospective Multicenter Trial HIT'91 (2007) (101)
Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features (2018) (101)
Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study (2009) (101)
Supratentorial ependymomas of childhood carry C11orf95–RELA fusions leading to pathological activation of the NF-κB signaling pathway (2014) (100)
Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis (2001) (100)
A highly conserved processed PTEN pseudogene is located on chromosome band 9p21 (1998) (99)
Glioneuronal Malformative Lesions and Dysembryoplastic Neuroepithelial Tumors in Pateints with Chroninc Pharmacoresistant Epilepsies (1995) (98)
Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor (2010) (96)
Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy (2014) (95)
Expression of the Neurotrophin Receptor p75NTR in Medulloblastomas Is Correlated with Distinct Histological and Clinical Features: Evidence for a Medulloblastoma Subtype Derived from the External Granule Cell Layer (2000) (95)
Hepatic stem‐like cells in hepatoblastoma: expression of cytokeratin 7, albumin and oval cell associated antigens detected by OV‐1 and OV‐6 (1997) (94)
Expression of stem-cell factor and its receptor c-kit protein in normal testicular tissue and malignant germ-cell tumours (2005) (93)
Epigenetic Silencing of the Protocadherin Family Member PCDH-γ-All in Astrocytomas (2005) (92)
Low Frequency of SV40, JC and BK Polyomavirus Sequences in Human Medulloblastomas, Meningiomas and Ependymomas (2000) (91)
A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma – A final report (2017) (89)
Xanthogranuloma, Rathke's cyst, and childhood craniopharyngioma: results of prospective multinational studies of children and adolescents with rare sellar malformations. (2012) (89)
A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma – A final report (2017) (89)
Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma (2015) (87)
Neural antigens in oligodendrogliomas and dysembryoplastic neuroepithelial tumors (1997) (83)
OTX1 and OTX2 Expression Correlates With the Clinicopathologic Classification of Medulloblastomas (2006) (82)
CT and MR imaging in atypical teratoid/rhabdoid tumors of the central nervous system (2008) (82)
Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study (2016) (81)
Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem (2012) (81)
Atypical Teratoid/Rhabdoid Tumors and Choroid Plexus Tumors: When Genetics “Surprise” Pathology (2003) (81)
Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: a prospective observational multicentre study. (2013) (81)
Role of radiotherapy in supratentorial primitive neuroectodermal tumor in young children: results of the German HIT-SKK87 and HIT-SKK92 trials. (2006) (81)
RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study (2009) (80)
Microsatellite analysis of loss of heterozygosity on chromosomes 9q, 11 p and 17p in medulloblastomas (1994) (79)
In vivo inhibition of angiogenesis and growth of the human U-87 malignant glial tumor by treatment with an antibody against basic fibroblast growth factor. (1995) (79)
Analysis of β-Catenin Gene Mutations in Pancreatic Tumors (1999) (79)
Characterization of five new cell lines derived from human primitive neuroectodermal tumors of the central nervous system. (1994) (78)
Analyses of Treatment Variables for Patients with Childhood Craniopharyngioma – Results of the Multicenter Prospective Trial KRANIOPHARYNGEOM 2000 after Three Years of Follow-Up (2008) (78)
Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells. (2010) (77)
High frequency of H3F3AK27M mutations characterizes pediatric and adult high-grade gliomas of the spinal cord (2015) (74)
Antitumoral Effects of Calcitriol in Basal Cell Carcinomas Involve Inhibition of Hedgehog Signaling and Induction of Vitamin D Receptor Signaling and Differentiation (2011) (74)
Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas. (2005) (73)
Natural history and management of low-grade glioma in NF-1 children (2010) (73)
Evidence of H3 K27M mutations in posterior fossa ependymomas (2016) (73)
Epigenetic Silencing of the HIC‐1 Gene in Human Medulloblastomas (2003) (73)
FGFR1 mutations in Rosette-forming glioneuronal tumors of the fourth ventricle. (2014) (72)
Activation of Phosphatidylinositol-3′-kinase/AKT Signaling Is Essential in Hepatoblastoma Survival (2009) (71)
The Molecular Landscape of ETMR at Diagnosis and Relapse (2019) (70)
Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy. (2013) (69)
Analysis of HIC‐1 methylation and transcription in human ependymomas (2004) (68)
Hepatocyte growth‐factor‐scatter factor can stimulate post‐operative tumor‐cell proliferation in childhood hepatoblastoma (2000) (67)
Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma (2001) (67)
Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma (2017) (67)
Large cell/anaplastic medulloblastoma: Outcome according to myc status, histopathological, and clinical risk factors (2010) (67)
Expression of receptors for granulocyte colony-stimulating factor on neutrophils from patients with severe congenital neutropenia and cyclic neutropenia. (1992) (66)
Thalamic high-grade gliomas in children: a distinct clinical subset? (2011) (65)
Heterogeneous regional expression patterns of matrix metalloproteinases in human malignant gliomas (1999) (62)
Neurochemical Profile of Glioneuronal Lesions from Patients with Pharmacoresistant Focal Epilepsies (1995) (61)
H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications? (2013) (61)
Mutations of the Wnt antagonist AXIN2 (Conductin) result in TCF‐dependent transcription in medulloblastomas (2007) (61)
High Expression of Somatostatin Receptor Subtype 2 (sst2) in Medulloblastoma: Implications for Diagnosis and Therapy (1999) (60)
Aberrant hypermethylation of the major breakpoint cluster region in 17p11.2 in medulloblastomas but not supratentorial PNETs (2001) (60)
Subtype‐specific expression and genetic alterations of the chemokinereceptor gene CXCR4 in medulloblastomas (2005) (60)
Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling. (2016) (60)
Childhood supratentorial ependymomas with YAP1‐MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features (2018) (60)
A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples. (2010) (59)
High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): a report from the European Rhabdoid Registry (EU-RHAB) (2014) (59)
Valproic Acid Prolongs Survival Time of Severe Combined Immunodeficient Mice Bearing Intracerebellar Orthotopic Medulloblastoma Xenografts (2006) (59)
Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas (2004) (58)
Insulin‐like growth factor‐1 receptor acts as a growth regulator in synovial sarcoma (2008) (58)
Indications for a tumor suppressor gene at 22q11 involved in the pathogenesis of ependymal tumors and distinct from hSNF5/INI1 (2001) (58)
Mutational and Expression Analysis of the NF1 Gene Argues Against a Role as Tumor Suppressor in Sporadic Pilocytic Astrocytomas (2002) (57)
Ependymoma of the spinal cord in children and adolescents: a retrospective series from the HIT database. (2010) (56)
Vascular Endothelial Growth Factor (VEGF) in Astrocytic Gliomas – A Prognostic Factor? (2004) (56)
Molecular pathogenesis of childhood brain tumors (2004) (55)
Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results (2010) (55)
Expression of coronin‐3 (coronin‐1C) in diffuse gliomas is related to malignancy (2007) (55)
Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system (2016) (55)
Childhood Craniopharyngioma – Changes of Treatment Strategies in the Trials KRANIOPHARYNGEOM 2000/2007 (2014) (54)
Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation. (2012) (54)
Differential control of VEGF synthesis and secretion in human glioma cells by IL-1 and EGF (1999) (53)
Update on the integrated histopathological and genetic classification of medulloblastoma – a practical diagnostic guideline (2016) (53)
Childhood pineoblastoma: experiences from the prospective multicenter trials HIT-SKK87, HIT-SKK92 and HIT91 (2006) (52)
A Rapid and Sensitive Protocol for Competitive Reverse Transcriptase (cRT) PCR Analysis of Cellular Genes (1998) (52)
Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial (2015) (52)
Expression of the c‐Kit receptor and its ligand SCF in non‐small‐cell lung carcinomas (1998) (51)
Subgroup-specific localization of human medulloblastoma based on pre-operative MRI (2014) (51)
Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma (2008) (51)
Diagnostic value of markers M2A, OCT3/4, AP‐2γ, PLAP and c‐KIT in the detection of extragonadal seminomas (2006) (50)
Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors (2019) (49)
Betulinic acid: a new chemotherapeutic agent in the treatment of neuroectodermal tumors. (1999) (49)
Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial (2018) (49)
p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19. (2000) (49)
Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07) (2018) (49)
Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide. (2012) (48)
Loss of heterozygosity on chromosome 1 in human hepatoblastoma (1996) (48)
Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma (2016) (48)
Impact of chemotherapy on disseminated low‐grade glioma in children and adolescents: Report from the HIT‐LGG 1996 trial (2011) (48)
Subpopulations of malignant gliomas in pediatric patients: analysis of the HIT-GBM database (2008) (48)
Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma (2017) (47)
SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma (2019) (46)
Aberrant methylation and reduced expression of LHX9 in malignant gliomas of childhood. (2009) (46)
Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumours (2015) (46)
Expression of Different Extracellular Matrix Components in Human Brain Tumor and Melanoma Cells in Respect to Variant Culture Conditions (1999) (45)
Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. (2016) (45)
Anaplastic ganglioglioma in children (2009) (44)
No evidence for the H133Y mutation in SONIC HEDGEHOG in a collection of common tumour types (1998) (43)
Blood mononuclear cells from patients with severe congenital neutropenia are capable of producing granulocyte colony-stimulating factor. (1991) (43)
Disseminated oligodendroglial cell-like leptomeningeal tumors: preliminary diagnostic and therapeutic results for a novel tumor entity (2015) (43)
Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging (2018) (43)
Microsatellite Instability in Pediatric and Adult High‐grade Gliomas (2007) (42)
WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma (2014) (42)
Epigenetic silencing of the candidate tumor suppressor gene PROX1 in sporadic breast cancer (2007) (42)
DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment (2018) (42)
Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. (2020) (41)
Treatment of children with central nervous system primitive neuroectodermal tumors/pinealoblastomas in the prospective multicentric trial HIT 2000 using hyperfractionated radiation therapy followed by maintenance chemotherapy. (2014) (40)
Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. (2015) (40)
Coexpression of stem cell factor and its receptor c-Kit in human malignant glioma cell lines (2004) (39)
EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. (2019) (39)
Epigenetic silencing of the candidate tumor suppressor gene PROX1 in sporadic breast cancer. (2005) (38)
HGNET-BCOR Tumors of the Cerebellum: Clinicopathologic and Molecular Characterization of 3 Cases (2017) (38)
High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D Pilot study (2011) (37)
LONG-TERM EFFICACY AND TOXICITY OF BEVACIZUMAB-BASED THERAPY IN CHILDREN WITH RECURRENT LOW-GRADE GLIOMAS (2012) (37)
Spinal cord injury-induced expression of the immune-regulatory chemokine interleukin-16 caused by activated microglia/macrophages and CD8+ cells. (2006) (37)
Production of interleukin‐1β and interleukin‐6 in hepatoblastoma (1993) (36)
Analysis of beta-catenin gene mutations in pancreatic tumors. (1999) (36)
Variable Imprinting of H19 and IGF2 in Fetal Cerebellum and Medulloblastoma (1996) (36)
Dolastatin 10 and dolastatin 15: effects of two natural peptides on growth and differentiation of leukemia cells. (1992) (36)
Extramedullary erythropoiesis in human liver grafts (1995) (36)
Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma (2019) (36)
Spinal Cord Ependymomas With MYCN Amplification Show Aggressive Clinical Behavior. (2019) (35)
Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data (2016) (35)
Expression of variant CD44 epitopes in human astrocytic brain tumors (1995) (35)
Pediatric high grade glioma of the spinal cord: results of the HIT-GBM database (2012) (34)
Molecular analysis of the lissencephaly gene 1 (LIS‐1) in medulloblastomas (1996) (34)
Analysis of the max‐binding protein MNT in human medulloblastomas (1999) (34)
Loss of heterozygosity at locus F13B on chromosome 1q in human medulloblastoma (1996) (34)
Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. (2019) (34)
Extramedullary Hematopoiesis and Intratumoral Production of Cytokines in Childhood Hepatoblastoma (1995) (34)
Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours (2012) (33)
Diffuse glioneuronal tumour with oligodendroglioma‐like features and nuclear clusters (DGONC) – a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14 (2019) (33)
CNS embryonal tumours: WHO 2016 and beyond (2018) (33)
P-glycoprotein modulation improves in vitro chemosensitivity in malignant pediatric liver tumors. (2003) (33)
Expression pattern of galectin‐3 in neural tumor cell lines (2000) (32)
Subcutaneous and intrahepatic growth of human hepatoblastoma in immunodeficient mice. (2006) (32)
Immunolocalization of granulocyte‐colony‐stimulating factor in human glial and primitive neuroectodermal tumors (1994) (32)
SGNE1/7B2 is epigenetically altered and transcriptionally downregulated in human medulloblastomas (2007) (32)
Strategies to improve the quality of survival for childhood brain tumour survivors. (2015) (31)
Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA (2019) (31)
Children <1 year show an inferior outcome when treated according to the traditional LGG treatment strategy: A report from the german multicenter trial HIT‐LGG 1996 for children with low grade glioma (LGG) (2014) (31)
Radiotherapy in pediatric pilocytic astrocytomas (2013) (31)
Tuberous sclerosis-like lesions in epileptogenic human neocortex lack allelic loss at the TSC1 and TSC2 regions (1996) (31)
Genome-wide DNA copy number analysis of desmoplastic infantile astrocytomas and desmoplastic infantile gangliogliomas. (2013) (31)
Genetic Analysis of Diffuse High‐Grade Astrocytomas in Infancy Defines a Novel Molecular Entity (2015) (30)
CNS germinomas are characterized by global demethylation, chromosomal instability and mutational activation of the Kit-, Ras/Raf/Erk- and Akt-pathways (2016) (30)
Metastatic medulloblastoma in adults: outcome of patients treated according to the HIT2000 protocol. (2015) (30)
PTEN mutations and activation of the PI3K/Akt/mTOR signaling pathway in papillary tumors of the pineal region. (2014) (30)
Prognostic impact of molecular genetic alterations in hepatoblastoma. (2002) (30)
Absence of KIAA1549-BRAF fusion in rosette-forming glioneuronal tumors of the fourth ventricle (RGNT) (2012) (30)
Mutations in the Nijmegen Breakage Syndrome Gene in Medulloblastomas (2008) (30)
Molecular Neuropathology of Astrocytic Brain Tumors (1997) (29)
Activation of the basal cell carcinoma pathway in a patient with CNS HGNET-BCOR diagnosis: consequences for personalized targeted therapy (2016) (29)
Supratentorial Primitive Neuroectodermal Tumors of the Central Nervous System in Adults: Molecular and Histopathologic Analysis of 12 Cases (2011) (29)
Vasoactive intestinal peptide (VIP) and VIP receptors: Gene expression and growth modulation in medulloblastoma and other central primitive neuroectodermal tumors of childhood (1999) (29)
Dominant-negative inhibition of Ets 1 suppresses tumor growth, invasion and migration in rat C6 glioma cells and reveals differentially expressed Ets 1 target genes. (2009) (29)
p53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease (2011) (29)
Supratentorial ependymoma in childhood: more than just RELA or YAP (2021) (28)
The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy (2014) (28)
Inactivation of Ets 1 transcription factor by a specific decoy strategy reduces rat C6 glioma cell proliferation and mmp-9 expression. (2005) (28)
Allelic loss at 10q23.3 but lack of mutation of PTEN/MMAC1 in chromophobe renal cell carcinoma. (2001) (28)
Giant Cell Glioblastoma Is Associated With Altered Aurora B Expression and Concomitant p53 Mutation (2010) (27)
Intramedullary gangliogliomas: histopathologic and molecular features of 25 cases. (2016) (27)
Pediatric atypical choroid plexus papilloma reconsidered: increased mitotic activity is prognostic only in older children (2015) (27)
Combination of Hedgehog Signaling Blockage and Chemotherapy Leads to Tumor Reduction in Pancreatic Adenocarcinomas (2012) (27)
Cerebellar location may predict an unfavourable prognosis in paediatric high-grade glioma (2013) (26)
YAP1/TAZ drives ependymoma-like tumour formation in mice (2020) (26)
RANK (TNFRSF11A) is epigenetically inactivated and induces apoptosis in gliomas. (2012) (25)
Systematic comparison of MRI findings in pediatric ependymoblastoma with ependymoma and CNS primitive neuroectodermal tumor not otherwise specified. (2015) (25)
ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial (2017) (25)
Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults (2019) (25)
Recurrence in childhood medulloblastoma (2011) (25)
No evidence for mutations or altered expression of the Suppressor of Fused gene (SUFU) in primitive neuroectodermal tumours (2004) (25)
Cervico‐medullary desmoplastic infantile ganglioglioma: An unusual case with diffuse leptomeningeal dissemination at diagnosis (2005) (25)
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma (2020) (24)
Molecular genetic studies in medulloblastomas: evidence for tumor suppressor genes at the chromosomal regions 1q31-32 and 17p13. (1997) (24)
High-Resolution Genomic Analysis Does Not Qualify Atypical Plexus Papilloma as a Separate Entity Among Choroid Plexus Tumors (2015) (24)
Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling (2018) (23)
Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma (2020) (23)
Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic Tumors. (2017) (23)
Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it? (2020) (23)
Type, Frequency, and Spatial Distribution of Immune Cell Infiltrates in CNS Germinomas: Evidence for Inflammatory and Immunosuppressive Mechanisms (2018) (23)
Differential imaging characteristics and dissemination potential of pilomyxoid astrocytomas versus pilocytic astrocytomas (2015) (23)
p75NTR induces apoptosis in medulloblastoma cells (2011) (23)
Analysis of KIAA1549‐BRAF fusion status in a case of rosette‐forming glioneuronal tumor of the fourth ventricle (RGNT) (2011) (23)
Somatic mitochondrial mutations in pilocytic astrocytoma. (2009) (22)
Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma (2018) (22)
Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy. (2015) (22)
WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial (2019) (22)
Surgical management of intracranial subependymomas (2011) (22)
Outcome of 11 children with ependymoblastoma treated within the prospective HIT-trials between 1991 and 2006 (2011) (21)
Clinical and epidemiological characteristics of pediatric gliosarcomas (2010) (21)
Absence of TERT promoter mutations in primary melanocytic tumours of the central nervous system (2014) (21)
Characterization of a continuous cell line (MHH-NB-11) derived from advanced neuroblastoma. (1988) (21)
Rhabdoid meningioma of the tentorium with expression of desmin in a 12-year-old Turner syndrome patient (2005) (20)
Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT'91--implications for investigating childhood medulloblastoma. (2007) (20)
Human medulloblastomas lack point mutations and homozygous deletions of the hSNF5/INI1 tumour suppressor gene (2002) (20)
Developmental expression and differentiation-related neuron-specific splicing of metastasis suppressor 1 (Mtss1) in normal and transformed cerebellar cells (2007) (20)
Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features – a retrospective analysis of the HIT ependymoma trial cohort (2019) (19)
Primary central nervous system primitive neuroectodermal tumors (CNS-PNETs) of the spinal cord in children: four cases from the German HIT database with a critical review of the literature (2011) (19)
Pediatric giant cell glioblastoma: New insights into a rare tumor entity. (2009) (19)
Do host factors determine long-term survival in glioblastoma? A genome/transcriptome profiling study by the German Glioma Network. (2014) (19)
Characterization of Neural Cell Lines Derived from SV40 Large T‐Induced Primitive Neuroectodermal Tumors (1997) (19)
PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum (2021) (19)
MRI Characteristics of Ependymoblastoma: Results from 22 Centrally Reviewed Cases (2014) (19)
Developmental-dependent DNA methylation of the IGF2 and H19 promoters is correlated to the promoter activities in human liver development. (1998) (18)
Minimal methylation classifier (MIMIC): A novel method for derivation and rapid diagnostic detection of disease-associated DNA methylation signatures (2017) (18)
Allelic loss but absence of mutations in the polyspecific transporter gene BWR1A on 11p15.5 in hepatoblastoma (2004) (18)
H3F3A-G34R mutant high grade neuroepithelial neoplasms with glial and dysplastic ganglion cell components (2019) (18)
Promoter-specific transcription of the IGF2 gene: a novel rapid, non-radioactive and highly sensitive protocol for mRNA analysis (2001) (18)
CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort (2020) (17)
Bone Involvement in Atypical Teratoid/Rhabdoid Tumors of the CNS (2013) (17)
Advances in Brief Childhood Hepatoblastomas Frequently Carry a Mutated Degradation Targeting Box of the b-Catenin Gene 1 (1999) (17)
Paracrine and autocrine growth mechanisms of human stem cell factor (c-kit ligand) in myeloid leukemia. (1993) (17)
Prognostic relevance of miRNA-155 methylation in anaplastic glioma (2016) (17)
A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastoma. (2012) (17)
Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma (2019) (17)
Genomic profiling reveals distinctive molecular relapse patterns in IDH1/2 wild‐type glioblastoma (2014) (17)
Postponed is not canceled: role of craniospinal radiation therapy in the management of recurrent infant medulloblastoma--an experience from the HIT-REZ 1997 & 2005 studies. (2014) (16)
Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. (2019) (16)
Medulloblastoma Harbor Somatic Mitochondrial DNA Mutations in the D-loop Region (2010) (16)
Primitive neuroectodermal tumors of the brainstem in children treated according to the HIT trials: clinical findings of a rare disease. (2015) (16)
FGFR1 N546K mutation in a case of papillary glioneuronal tumor (PGNT) (2014) (16)
Serum levels of stem cell factor are increased in asymptomatic human immunodeficiency virus-infected patients and are associated with prolonged survival. (1995) (15)
The FDA approved PI3K inhibitor GDC‐0941 enhances in vitro the anti‐neoplastic efficacy of Axitinib against c‐myc‐amplified high‐risk medulloblastoma (2018) (15)
Absence of detectable alterations in the putative tumor suppressor gene BTRC in cerebellar medulloblastomas and cutaneous basal cell carcinomas (2003) (15)
MYCN amplification predicts poor outcome for patients with supratentorial primitive neuroectodermal tumors of the central nervous system . (2014) (15)
Meningioma as second malignant neoplasm after oncological treatment during childhood (2012) (15)
PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomas. (2004) (15)
MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma (2018) (15)
Curative treatment for central nervous system medulloepithelioma despite residual disease after resection (2011) (15)
Effects of Granulocyte Colony-Stimulating Factor in Children with Severe Congenital Neutropenia (1992) (15)
Different vascular patterns of medulloblastoma and supratentorial primitive neuroectodermal tumors (1999) (14)
Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood (2019) (14)
Low level of microsatellite instability in paediatric malignant astrocytomas (2008) (14)
Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide (2019) (14)
Abstract 3463: Treatment of young children with localized medulloblastoma by chemotherapy alone: Final results of the prospective multicenter trial HIT 2000 confirming the prognostic impact of histology (2011) (14)
Early Wound Site Seeding in a Patient with Central Nervous System High-Grade Neuroepithelial Tumor with BCOR Alteration. (2018) (14)
Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors (2016) (14)
Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification (2017) (14)
Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma. (2021) (13)
Cerebellar medullomyoblastoma with melanotic tubular structures (2008) (13)
A Global View on the Availability of Methods and Information in the Neuropathological Diagnostics of CNS Tumors: Results of an International Survey Among Neuropathological Units (2016) (13)
Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group. (2018) (13)
Erratum to: Disseminated oligodendroglial-like leptomeningeal tumors: preliminary diagnostic and therapeutic results for a novel tumor entity (2015) (13)
Medullomyoblastoma: a histological, immunohistochemical, ultrastructural and molecular genetic study (1998) (13)
A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study (2013) (13)
Pathology and Classification of Tumors of the Nervous System (2010) (13)
Animal model of human medulloblastoma: clinical, magnetic resonance imaging, and histopathological findings after intra-cisternal injection of MHH-MED-1 cells into nude rats. (1997) (13)
Dysembryoplastic Neuroepithelial Tumor of the Septum Pellucidum and the Supratentorial Midline: Histopathologic, Neuroradiologic, and Molecular Features of 7 Cases (2016) (13)
Loss of efficacy of subsequent nonsurgical therapy after primary treatment failure in pediatric low‐grade glioma patients—Report from the German SIOP‐LGG 2004 cohort (2020) (13)
Chromosomal imbalances and DNA amplifications in SV40 large T antigen-induced primitive neuroectodermal tumor cell lines of the rat. (1999) (13)
Sensitive Determination of BRAF Copy Number in Clinical Samples by Pyrosequencing (2011) (13)
Management of primary thalamic low-grade glioma in pediatric patients: results of the multicenter treatment studies HIT-LGG 1996 and SIOP-LGG 2004. (2017) (12)
Medulloblastoma Displays Distinct Regional Matrix Metalloprotease Expression (2001) (12)
Primary intracranial soft tissue sarcoma in children and adolescents: a cooperative analysis of the European CWS and HIT study groups (2013) (12)
[Gastrointestinal stromal tumors carrying PDGFRalpha mutations occur preferentially in the stomach and exhibit an epithelioid or mixed phenotype]. (2004) (12)
Management of Primary Tectal Plate Low-Grade Glioma in Pediatric Patients: Results of the Multicenter Treatment Study SIOP-LGG 2004 (2018) (12)
Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome (2020) (12)
Local and Systemic Therapy of Recurrent Ependymoma in Children and Adolescents: Short- and Long-term Results of the E-HIT-REZ 2005 Study. (2020) (12)
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab) (2020) (12)
New developments in the pathology of skull base tumors (2001) (12)
Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas (2009) (12)
Rare ADAR and RNASEH2B variants and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis (2017) (12)
Pediatric ependymoma: an overview of a complex disease (2021) (12)
Alternative lengthening of telomeres in molecular subgroups of paediatric high-grade glioma (2020) (11)
FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas (2019) (11)
Absence of chromosome 19q13.41 amplification in a case of atypical teratoid/rhabdoid tumor with ependymoblastic differentiation (2011) (11)
Expression of granulocyte colony-stimulating factor in recurrent glial tumors is inversely correlated with tumor progression (1999) (11)
Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen (2018) (11)
Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor (2019) (11)
Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma (2013) (11)
Case of the month 1-2019: CNS high-grade neuroepithelial tumor with BCOR alteration (2018) (11)
Long-term cognitive deficits in pediatric low-grade glioma (LGG) survivors reflect pretreatment conditions—report from the German LGG studies (2020) (10)
Metabolic studies of human primitive neuroectodermal tumour cells by proton nuclear magnetic resonance spectroscopy. (1997) (10)
Human peripheral blood granulocytes and myeloid leukemic cell lines express both transcripts encoding for stem cell factor (1994) (10)
Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma – A Report From the HIT 2000 Trial (2020) (10)
Occurrence of high‐grade glioma in Noonan syndrome: Report of two cases (2019) (10)
Therapeutic implications of improved molecular diagnostics for rare CNS-embryonal tumor entities: results of an international, retrospective study. (2021) (10)
Molecular characterization of disseminated pilocytic astrocytomas (2016) (10)
Differential forms of p53 in medulloblastoma primary tumors, cell lines and xenografts. (2011) (10)
CD95 ligand-induced apoptosis of human medulloblastoma cells. (1998) (10)
Concurrent IDH1 and SMARCB1 Mutations in Pediatric Medulloblastoma: A Case Report (2018) (10)
Frequent epigenetic inactivation of the chaperone SGNE1/7B2 in human gliomas (2012) (9)
Musashi1 enhances chemotherapy resistance of pediatric glioblastoma cells in vitro (2019) (9)
Identification of amplified genes from SV40 large T antigen-induced rat PNET cell lines by subtractive cDNA analysis and radiation hybrid mapping (2001) (9)
Ependymoblastoma of the brainstem: MRI findings and differential diagnosis (2014) (9)
Paucimannosidic glycoepitopes inhibit tumorigenic processes in glioblastoma multiforme (2019) (9)
Monoclonal antibody T-199 directed against human medulloblastoma: characterization of a new antigenic system expressed on neuroectodermal tumors and natural killer cells. (1989) (9)
Favorable prognosis in pediatric brainstem low‐grade glioma: Report from the German SIOP‐LGG 2004 cohort (2020) (9)
Production of interleukin-1 beta and interleukin-6 in hepatoblastoma. (1993) (9)
Analysis of the TSC2 gene in human medulloblastoma (2001) (9)
CRX/OTX3: A Useful Marker in the Differential Diagnosis of Tumors of the Pineal Region and Indicator of Photoreceptor Differentiation in Medulloblastomas and Atypical Teratoid Rhabdoid Tumors (2013) (9)
Rare histological variants in ependymomas: histopathological analysis of 13 cases (2011) (8)
Altered splicing leads to reduced activation of CPEB3 in high-grade gliomas (2016) (8)
Unusual clinico-pathological features in primary Hodgkin’s lymphomas of the central nervous system (2012) (8)
Proportion of children with cancer that have an indication for genetic counseling and testing based on the cancer type irrespective of other features (2021) (8)
Extracranial metastasizing solitary fibrous tumors (SFT) of meninges: Histopathological features of a case with long‐term follow‐up (2013) (8)
What’s in a name? (2013) (8)
The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition (2017) (8)
Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making — A Selected Case Series (2018) (8)
The diagnostic role and clinical relevance of determination of BRAF status in brain tumors. (2013) (8)
Assessment of Promoter Methylation Identifies PTCH as a Putative Tumor-suppressor Gene in Human CLL. (2016) (8)
High frequency of disease progression in pediatric spinal cord low-grade glioma (LGG): Management strategies and results from the German LGG study group. (2020) (8)
HIGH GRADE GLIOMAS (2012) (8)
Spinal cord injury-induced expression of the antiangiogenic endostatin/collagen XVIII in areas of vascular remodelling. (2007) (7)
Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link? (2021) (7)
Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of MGMT Promoter Methylation Status (2021) (7)
Frequent intragenic polymorphism in the 3‘ untranslated region of the lissencephaly gene 1 (LIS‐1) (1996) (7)
Adults with CNS primitive neuroectodermal tumors/pineoblastomas: results of multimodal treatment according to the pediatric HIT 2000 protocol (2014) (7)
High-Resolution Genomic Analysis of Cribriform Neuroepithelial Tumors of the Central Nervous System (2015) (7)
Doubling Recruitment of Pediatric Low-grade Glioma within Two Decades does not change Outcome – Report from the German LGG Studies (2021) (7)
OTX2 Defines a Subgroup of Atypical Teratoid Rhabdoid Tumors With Close Relationship to Choroid Plexus Tumors (2016) (7)
Transthyretin expression in medulloblastomas and medulloblastoma cell lines (1995) (7)
Ablation of T cell immunity differentially influences tumor risk in inbred BD rat strains (2009) (6)
EGFR gene amplification and variant III (EGFRvIII) mutation in primary and recurrent glioblastoma. (2016) (6)
MTSS1 is epigenetically regulated in glioma cells and inhibits glioma cell motility (2016) (6)
Specificity and functional effects of antibodies to human stem cell factor. (1997) (6)
Clinical, pathological, and molecular data on desmoplastic/nodular medulloblastoma: case studies and a review of the literature (2016) (6)
Imaging Characteristics of Wingless Pathway Subgroup Medulloblastomas: Results from the German HIT/SIOP-Trial Cohort (2019) (6)
Concordance between local, institutional, and central pathology review in glioblastoma: implications for research and practice: a pilot study. (2012) (6)
[Inhibition of angiogenesis and growth of malignant gliomas in the athymic nude rat model: immunotherapy against "basic fibroblast growth factor"]. (1996) (6)
Prognostic impact of distinct genetic entities in pediatric diffuse glioma WHO‐grade II—Report from the German/Swiss SIOP‐LGG 2004 cohort (2020) (6)
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA‐09 trial (2020) (5)
Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1 (2019) (5)
Voltage- and γ-aminobutyric acid-activated membrane currents in the human medulloblastoma cell line MHH-MED-3 (2000) (5)
Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors (2021) (5)
Natural history of a medulloblastoma: 30 months of wait and see in a child with a cerebellar incidentaloma (2013) (5)
Hepatic stem cells in the human liver (1996) (5)
NEURO/MEDICAL ONCOLOGY (2013) (4)
DNA methylation profiling improves routine diagnosis of paediatric central nervous system tumours: A prospective population‐based study (2022) (4)
Mitogenic Effect of Human Stem Cell Factor Alone or in Combination with G-CSF, GM-CSF, and IL-3 on Fresh Leukemic Blasts from Patients with Stem Cell Factor Receptor-Positive Acute Myeloid Leukemia (1992) (4)
MBCL-07. NON-METASTATIC MEDULLOBLASTOMA OF EARLY CHILDHOOD: RESULTS FROM THE PROSPECTIVE CLINICAL TRIAL HIT-2000 AND AN EXTENDED VALIDATION COHORT (2020) (4)
Treatment of Embryonal Tumours with Multilayered Rosettes with Carboplatin/Etoposide Induction and High-dose Chemotherapy within the Prospective P-HIT Trial. (2021) (4)
Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3 K27M Mutant Diffuse Midline Glioma (2021) (4)
MHH-ES-1, A new Ewing sarcoma cell line (1989) (4)
Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas (2021) (4)
Human stem cell factor is a growth factor for myeloid leukemia cells. (1993) (4)
BI-32RISK FACTOR ANALYSIS FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WHO DID NOT RECEIVE SALVAGE THERAPY (2014) (4)
Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts (2022) (4)
Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas (2022) (4)
Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies (2021) (4)
A Marker for Diffuse High-Grade Astrocytomas (2016) (4)
Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups. (2021) (4)
ATRT–SHH comprises three molecular subgroups with characteristic clinical and histopathological features and prognostic significance (2022) (3)
G-PCNSL-SG-1 randomized phase III trial of high-dose methotrexate with or without whole brain radiotherapy for primary central nervous system lymphoma: Long-term follow-up. (2014) (3)
Histopathological grading of intracranial pediatric ependymomas (2008) (3)
MET T992I mutation in a case of ependymoblastoma/embryonal tumour with multilayered rosettes (2014) (3)
Medulloblastoma with extensive nodularity: a tumour exclusively of infancy? (2017) (3)
Durable response to mTOR inhibition in a patient with relapsing papillary tumor of the pineal region (2018) (3)
Mutated SON putatively causes a cancer syndrome comprising high-risk medulloblastoma combined with café-au-lait spots (2019) (3)
Pathology and Classification of Tumors of the Central Nervous System (2019) (3)
Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment (2021) (3)
GCT-76. 24Gy WHOLE VENTRICULAR RADIOTHERAPY ALONE IS SUFFICIENT FOR DISEASE CONTROL IN LOCALISED GERMINOMA IN CR AFTER INITIAL CHEMOTHERAPY – EARLY RESULTS OF THE SIOP CNS GCT II STUDY (2020) (3)
Supplemental Information New Brain Tumor Entities Emerge from Molecular Classi fi cation of CNS-PNETs (2016) (3)
EMBR-15. DIAGNOSTIC RE-EVALUATION AND POOLED CLINICAL DATA ANALYSIS OF PATIENTS WITH PREVIOUS DIAGNOSIS OF CNS-PNET (2018) (3)
1q gain is a frequent finding in preoperatively treated Wilms tumors, but of limited prognostic value for risk stratification in the SIOP2001/GPOH trial (2014) (3)
Determining the glioma CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide methylation data in the biomarker cohort of the NOA-04 trial. (2014) (3)
MBCL-39. MEDULLOBLASTOMA IN PATIENTS WITH GORLIN SYNDROME: RESULTS FROM THE HIT STUDY GROUP (2018) (2)
Combinatorial effects of azacitidine and trametinib on NRAS‐mutated melanoma (2021) (2)
MB-89TREATMENT FAILURE IN YOUNG CHILDREN WITH DESMOPLASTIC MEDULLOBLASTOMA (DMB)/MEDULLOBLASTOMA WITH EXTENSIVE NODULARITY (MBEN) TREATED ACCORDING TO THE HIT PROTOCOLS. (2016) (2)
LG-63MANAGEMENT OF PRIMARY TECTAL LOW-GRADE GLIOMA (LGG) IN PEDIATRIC PATIENTS: RESULTS OF THE MULTICENTER TREATMENT STUDY SIOP-LGG 2004 (2016) (2)
Using CRISPR/Cas9 genome editing in human iPSCs for deciphering the pathogenicity of a novel CCM1 transcription start site deletion (2022) (2)
Evaluation of dose, volume, and outcome in children with localized, intracranial ependymoma treated with proton therapy within the prospective KiProReg Study (2021) (2)
LGG-23. REPEATED PROGRESSIONS IN PEDIATRIC CHIASMATIC-HYPOTHALAMIC GLIOMAS (CHG): CAN WE IDENTIFY SUCCESSFUL TREATMENT STRATEGIES? (2018) (2)
Clinical and molecular subgroups of ependymoma in adulthood: An analysis of the German Glioma Network. (2017) (2)
Quality assurance in neuropathology: Experiences from the round robin trials on IDH mutation and MGMT promoter methylation testing launched by the Quality Assurance Initiative Pathology (QuIP) in 2018 and 2019. (2020) (2)
INCIDENTAL NEUROPATHOLOGICAL FINDINGS IN A CHILD WITH CERVICAL MENINGORADICULOCELE (2012) (2)
No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany (2021) (2)
Hypothalamic papillary tumor in a patient with tuberous sclerosis. (2008) (2)
Effects of the growth pattern of medulloblastoma on short-term neurological impairments after surgery: results from the prospective multicenter HIT-SIOP PNET 4 study. (2020) (2)
Molecular heterogeneity characterizes glioblastoma with lipoblast/adipocyte-like cytology (2015) (2)
Integrative Genomic Analyses of Atypical Teratoid Rhabdoid Tumours (ATRTs) (2014) (2)
Xanthogranuloma, Rathkes cyst, and Childhood Craniopharyngioma: results of prospective multinational studies of children and adolescents with rare sellar malformations (2013) (2)
Initial hypothalamic involvement is the major risk factor for impaired prognosis and quality of life in childhood craniopharyngioma regardless of chosen treatment strategies: results of KRANIOPHARYNGEOM 2000 (2012) (2)
Group 3 medulloblastoma in a patient with a GYS2 germline mutation and glycogen storage disease 0a (2018) (2)
[Neuropathology of medulloblastomas and other CNS embryonal tumors : Precision diagnostics through the integration of genetic markers]. (2019) (2)
EMBR-08. CHOROID PLEXUS TUMORS IN 2018: THE CPT-SIOP EXPERIENCE AND LONG-TERM OUTCOME (2018) (2)
GENE-08. THE MNP 2.0 STUDY: PROSPECTIVE INTEGRATION OF DNA METHYLATION PROFILING IN CNS TUMOR DIAGNOSTICS (2019) (2)
RANK ( TNFRSF 11 A ) Is Epigenetically Inactivated and Induces Apoptosis in Gliomas 1 , 2 (2014) (2)
p57 Is Not Mutated in Hepatoblastoma but Shows Increased Transcriptional Activity in a Comparative Analysis of the Three Imprinted Genes p57, IGF2, and H19 (2000) (2)
Clinical Epidermal Growth Factor Receptor Variant III ( EGFRvIII ) Positivity in EGFR-Ampli fi ed Glioblastomas : Prognostic Role and Comparison between Primary and Recurrent Tumors (2017) (2)
Xanthogranuloma of the sellar region – Results of a multicenter prospective study on diagnostics, therapy and prognosis in children and adolescents (2008) (1)
Clinical and molecular features associated with long-term survival of elderly patients with glioblastoma. (2017) (1)
Late complete remission of supratentorial primitive neuroectodermal tumor (CNS‐PNET) after multiple relapses (2011) (1)
PNR-33MOLECULAR RE-EVALUATION OF INSTITUTIONALLY DIAGNOSED CNS-PNETS: CLINICAL CONSEQUENCES OF CONFINED DIAGNOSTIC GROUPS (2016) (1)
Pediatric high-grade gliomas and the WHO CNS Tumor Classification—Perspectives of pediatric neuro-oncologists and neuropathologists in light of recent updates (2022) (1)
Abstract LB-384: Targeting overexpressed Aurora kinases in childhood medulloblastoma: Antiproliferative effects of small molecule inhibitors ZM44739, VX680 and shRNA (2010) (1)
Long-term survival in primary glioblastoma revisited: The contribution of isocitrate dehydrogenase mutations. (2013) (1)
Abstract 1446: Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem (2012) (1)
New developments and controversies in the neuropathology of malignant gliomas. (1999) (1)
EPEN-39. CLINICAL STRATIFIED TREATMENT OF LOCALIZED PEDIATRIC INTRACRANIAL EPENDYMOMA WITH COMBINED LOCAL IRRADIATION AND CHEMOTHERAPY WITHIN THE PROSPECTIVE, MULTICENTER E-HIT TRIAL – THE MOLECULAR SUBGROUP MATTERS (2020) (1)
TB-11MOLECULAR NEUROPATHOLOGY 2.0 - INCREASING DIAGNOSTIC ACCURACY IN PEDIATRIC NEUROONCOLOGY (2016) (1)
ETMR-14. TREATMENT OF EMBRYONAL TUMOURS WITH MULTILAYERED ROSETTES (ETMR) WITH CARBOPLATIN-ETOPOSIDE INDUCTION AND TANDEM HIGH-DOSE CHEMOTHERAPY WITHIN THE PROSPECTIVE HIT-TRIALS AND REGISTRIES (2020) (1)
Polyclonal Resistance in Gastrointestinal Stromal Tumor Treated with Sequential Kinase Inhibitors (2006) (1)
Long-term follow-up of surgical intervention pattern in pediatric low-grade gliomas: report from the German SIOP-LGG 2004 cohort. (2022) (1)
Current status of phase III anti-EGF-receptor antibody (OSAG-101) for newly diagnosed glioblastoma. (2010) (1)
Preclinical target analyisis in pediatric malignancies for selecting targeted compounds: Innovative therapies for children with cancer. (2005) (1)
Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study (2022) (1)
Post-Operative Hypothalamic Lesions and Obesity in Childhood Craniopharyngioma - Results of the Multinational Prospective Trial KRANIOPHARYNGEOM 2000 after Three Year Follow-up (2473 words) short running title: Hypothalamic lesions in childhood craniopharyngioma (2011) (1)
Targeting HSP90 in pediatric malignancies by the European Consortium "Innovative Therapies for Children with Cancer" (2007) (1)
ACTR-53. MGMT PROMOTER METHYLATION ANALYSIS FOR ALLOCATING COMBINED CCNU/TMZ CHEMOTHERAPY: LESSONS LEARNED FROM THE CeTeG/NOA-09 TRIAL (2019) (1)
Shows Increased Transcriptional Activity in a Comparative Analysis of the Three Imprinted Genes (2000) (1)
EPEN-07. EPENDYMOMAS IN INFANCY: UNDERLYING GENETIC ALTERATIONS, HISTOLOGICAL FEATURES AND CLINICAL OUTCOME (2019) (1)
Defining the Spectrum, Treatment and Outcome of Patients With Genetically Confirmed Gorlin Syndrome From the HIT-MED Cohort (2021) (1)
First randomized multicenter study in patients with childhood craniopharyngioma analyzing the appropriate time point of irradiation after incomplete resection – study design of KRANIOPHARYNGEOM 2007 (2006) (1)
Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS (2022) (1)
Author Correction: YAP1/TAZ drives ependymoma-like tumour formation in mice (2020) (1)
OMICS AND PROGNSTIC MARKERS (2013) (1)
MBCL-21. EARLY CHILDHOOD MEDULLOBLASTOMA: SUBGROUP-SPECIFIC SURVIVAL IN PATIENTS TREATED WITH SYSTEMIC CHEMOTHERAPY AND INTRAVENTRICULAR MTX TO AVOID CRANIOSPINAL RADIOTHERAPY (2018) (1)
Abstract 2492: Integrated genomics on molecular subgroups in medulloblastoma (2012) (1)
Deciphering the real incidence of medulloblastoma with extensive nodularity in adult patients (2016) (1)
OT-10IMPLEMENTATION OF NEXT GENERATION COPY NUMBER AND MUTATIONAL ANALYSIS IN ROUTINE NEUROPATHOLOGY: MOLECULAR INVERSION PROFILING IS A HELPFUL TOOL IN DIFFERENTIAL DIAGNOSTICS AND PROGNOSTIFICATION OF PEDIATRIC BRAIN TUMORS (2015) (1)
Correspondence re: J. Benítez et al., A region of allelic imbalance in 1q31-32 in primary breast cancer coincides with a recombination hot spot. Cancer Res., 57: 4217-4220, 1997. (1998) (1)
PEDIATRICS CLINICAL RESEARCH (2010) (1)
Abstract LB-83: Molecular stratification of medulloblastoma: comparison of histological and genetical methods to detect Wnt activated tumors. (2013) (1)
Pediatric neuro-oncology in small centers--quality control of network support: the HIT-GBM experience. (2011) (1)
Molecular classification of diffuse cerebral gliomas using genome- and transcriptome-wide profiling. (2015) (1)
NFM-11. PEDIATRIC MENINGIOMAS ARE MOLECULARLY DISTINCT FROM ADULT COUNTERPARTS (2018) (1)
LG-06MANAGEMENT OF PRIMARY THALAMIC LOW-GRADE GLIOMA IN PEDIATRIC PATIENTS: RESULTS OF THE MULTICENTER TREATMENT STUDIES HIT-LGG 1996 AND SIOP-LGG 2004 (2016) (1)
MB-24ROUTINE DIAGNOSTIC MEDULLOBLASTOMA SUBGROUPING USING LOW-COST, LOW-INPUT DNA METHYLOMICS: APPLICATION TO TRIALS COHORTS PREVIOUSLY REFRACTORY-TO-ANALYSIS (2016) (1)
Transitioning to molecular diagnostics in pediatric high-grade glioma: experiences with the 2016 WHO classification of CNS tumors (2021) (1)
AT-59HIGH-DOSE MTX-BASED CHEMOTHERAPY FOR PRIMARY CNS LYMPHOMA: WITH OR WITHOUT WHOLE BRAIN RADIOTHERAPY? FINAL ANALYSIS OF G-PCNSL-SG-1 (2014) (1)
Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology (2023) (1)
The PI3K inhibitor pictilisib and the multikinase inhibitors pazopanib and sorafenib have an impact on Rac1 level and migration of medulloblastoma in vitro (2022) (1)
TBIO-07. ASSESSING THE UTILITY OF DNA METHYLATION PROFILING IN BRAIN TUMOR DIAGNOSTICS—THE PROSPECTIVE MNP2.0 STUDY (2018) (0)
MB-46PROGNOSTIC RELEVANCE OF EPIGENETIC/BIOLOGICAL SUBGROUPS AND MYCC/MYCN GENE AMPLIFICATION IN A HOMOGENOUSLY TREATED METASTATIC MEDULLOBLASTOMA HIT2000 COHORT AGED 4-21 YEARS (2016) (0)
PNR-09EVALUATION OF AGE-DEPENDENT TREATMENT STRATEGIES FOR CHILDREN AND YOUNG ADULTS WITH PINEOBLASTOMA: ANALYSIS OF POOLED SIOP-E AND HEAD START DATA (2016) (0)
HGG-16. Final analysis of the HIT-HGG-2007 trial (ISRCTN19852453): Significant survival benefit for pontine and non-pontine pediatric high-grade gliomas in comparison to previous HIT-GBM-C/-D trials. (2022) (0)
MPTH-23. LONG-TERM SURVIVAL WITH GLIOBLASTOMA IN THE ELDERLY (2016) (0)
Deciphering the AT/RT ligandome (2018) (0)
HGG-59. Pediatric high-grade gliomas and the WHO classification on CNS Tumors - Different perspectives of pediatric neuro-oncologists and neuropathologists in the light of recent updates (2022) (0)
MEDB-37. Chemotherapy response prediction by molecular risk factors in metastatic childhood medulloblastoma (2022) (0)
PNR-25ETMR—FREQUENCY, CLINICAL PRESENTATION, TREATMENT AND OUTCOME OF 29 PATIENTS TREATED WITHIN THE HIT TRIALS (2016) (0)
GCT-11. 24 Gy whole ventricular radiotherapy alone is sufficient for disease control in localised germinoma in CR after initial chemotherapy – final of the SIOP CNS GCT II study (2022) (0)
Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies (2022) (0)
CSIG-27. DIFFERENTIAL ELEVATION OF TERT ACTIVITY AND SENSITIVITY TO TEMOZOLOMIDE BY TYPE OF TERT MUTATION IN MGMT PROMOTER-METHYLATED GLIOBLASTOMA (2018) (0)
HGG-34. DETECTION OF ONCOGENIC FUSION EVENTS IN SUPRATENTORIAL GLIOBLASTOMAS OF YOUNG CHILDREN (2020) (0)
ATRT-15. SPINAL CORD ATYPICAL TERATOID/RHABDOID TUMORS (AT/RT) IN CHILDREN: RESULTS OF A EUROPEAN RETROSPECTIVE ANALYSIS UNDER THE AUSPICES OF THE EU-RHAB STUDY GROUP (2018) (0)
MBCL-09. ISOLATED M1 METASTASES IN PEDIATRIC MEDULLOBLASTOMA: IS POSTOPERATIVE RADIOTHERAPY FOLLOWED BY MAINTENANCE CHEMOTHERAPY SUPERIOR TO POSTOPERATIVE SANDWICH-CHEMOTHERAPY AND RADIOTHERAPY? (2020) (0)
Expression of drugable targets in pediatric malignancies: Innovative therapies for children with cancer (2007) (0)
MEDB-61. Genetic alterations ofTP53 andOTX2 indicate increased risk of relapse in WNT medulloblastomas (2022) (0)
Medulloblastoma in adults: identifying imaging biomarkers of genetic status in a prospective multi-centre study (2017) (0)
GCT-48. OUTCOME OF CNS MALIGNANT NON-GERMINOMATOUS GERM CELL TUMORS (GCT) WITH AFP > 1000 ng/ml AT DIAGNOSIS TREATED ACCORDING TO SIOP CNS GCT 96 (2020) (0)
First Report of Glioblastoma and Associated PNKP Mutation (2021) (0)
QOL-04. Histology, treatment, and extent of pretreatment hydrocephalus are major determents of neurocognitive outcome for survivors of pediatric posterior fossa tumors - report from the German HIT-studies (2022) (0)
Risk prediction in early childhood SHH medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than two subgroups. (2023) (0)
Glioblastoma centre and periphery: two aspects of the same disease (2009) (0)
MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome (2022) (0)
Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features – a retrospective analysis of the HIT ependymoma trial cohort (2019) (0)
A 78‐Year‐Old Male with a Right Occipital Lesion (2013) (0)
OS2.2 Chemotherapy for spinal gliomas in adults (2019) (0)
Unearthing Hidden Genomic Data in Solid Tumor Samples: Are Your FFPE Samples Revealing All? (2013) (0)
Abstract 1432: The heterogeneous genomic landscape of posterior fossa ependymoma (2012) (0)
RARE-12. Pineoblastoma of children and young adults in a national population: An analysis of the HIT-MED study cohort (2022) (0)
COMMENT ON : A REGION OF ALLELIC IMBALANCE IN 1Q31-32 IN PRIMARY BREAST CANCER COINCIDES WITH A RECOMBINATION HOT SPOT BY J. BENITEZ ET AL. (1998) (0)
Abstract 4702: Chromosome 2p gain andN-Mycamplification predict poor outcome of patients with LIN28 negative supratentorial primitive neuroectodermal tumors of the central nervous system (CNS-PNET).. (2013) (0)
HIGH GRADE GLIOMAS AND DIPG (2014) (0)
PATH-08. DNA methylation profiling improves routine diagnostics of paediatric CNS tumours: a prospective population-based study (2022) (0)
ETMR-10. Retrospective molecular re-evaluation of CNS PNETs; a population-based study (2022) (0)
Minimal methylation classifier (MIMIC): A novel method for derivation and rapid diagnostic detection of disease-associated DNA methylation signatures (2017) (0)
PATH-13. PLEOMORPHIC XANTHOASTROCYTOMA INTEGRATED GENOMIC CHARACTERIZATION - WHAT HAVE WE LEARNED? (2020) (0)
PATH-24. MOLECULAR SUBGROUPS OF ADULT EPENDYMAL TUMORS: AN ANALYSIS OF THE GERMAN GLIOMA NETWORK (2017) (0)
13 INVITED KidsCancerKinome: a EU-FP6 project for preclinical kinase inhibitor evaluation as a tool to prioritize compounds for paediatric development (2008) (0)
Clinical and pathologic data of 32 patients with GISTs under imatinib treatment (2006) (0)
HG-85INTER-OBSERVER AGREEMENT IN NEUROPATHOLOGICAL HGG DIAGNOSIS : EXPERIENCE OF THE PRE-RANDOMISATION CENTRAL REVIEW IN THE HERBY TRIAL. (2016) (0)
ACTIVATION OF THE HEDGEHOG-PATCHED-SIGNALING PATHWAY IN PANCREATIC ADENOCARCINOMAS (2005) (0)
Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma (2018) (0)
EMBR-25. GENOME-WIDE GENETIC AND EPIGENETIC ASSESSMENT OF GROUP 4 MEDULLOBLASTOMA FOR IMPROVED, BIOMARKER DRIVEN, PROGNOSTICATION AND RISK-STRATIFICATION (2021) (0)
Biochemical Characterization and Regulation of Expression of the Binding Protein for the Granulocyte Colony-Stimulating Factor on Leukemia Cells (1992) (0)
Meningiomas in childhood and adolescence – Multicenter cross-sectional study on 42 patients (2008) (0)
MPTH-52. GENOMIC LANDSCAPE OF ADULT MEDULLOBLASTOMAS CLASSIFIED ACCORDING TO WHO 2016 GUIDELINES (2016) (0)
Abstract LB-205: Genome-wide copy number analysis of pediatric hepatocellular carcinomas: Identification of characteristic aberrations (2014) (0)
Optimising biomarkers for accurate ependymoma diagnosis, prognostication and stratification within International Clinical Trials: A BIOMECA study (2022) (0)
Chemotherapy for adult patients with spinal cord gliomas. (2021) (0)
MEDB-68. Analysis of telomeres length and Alternative Lengthening of Telomeres (ALT) in molecular subgroups of infant medulloblastoma (2022) (0)
Synthesis and Neoangiogenesis ( Flt-1 ) / Vascular Endothelial Growth Factor Receptor-1 Astrocytomas Is Associated with Fms-like Tyrosine Kinase-1 Expression of the Ets-1 Transcription Factor in Human Updated (1999) (0)
CTNI-67. DUAL INHIBITION OF POST-RADIOGENIC ANGIO-VASCULOGENESIS BY OLAPTESED PEGOL (NOX-A12) AND BEVACIZUMAB IN GLIOBLASTOMA – INTERIM DATA FROM THE FIRST EXPANSION ARM OF THE GERMAN PHASE 1/2 GLORIA TRIAL (2022) (0)
Human Stem Cell Factor: Biological Effects and Receptor Expression on Myeloid Leukemia Cells (1992) (0)
EPEN-24. Biological markers of ependymoma in children and adolescents (BIOMECA): Systematic comparison of methods for the precise evaluation of biomarkers for ependymoma diagnosis and prognostication (2022) (0)
Abstract LB-82: Chromosome 1q gain as genetic marker for risk stratification of pediatric ependymoma patients - validation as an adverse prognostic marker in the German multicenter HIT2000 trial. (2013) (0)
MBCL-31. A WHOLE CHROMOSOME ABERRATION PHENOTYPE IN NON-WNT/NON-SHH TUMORS PREDICTS OUTCOME WITHIN STANDARD-RISK MEDULLOBLASTOMAS FROM THE HIT-SIOP-PNET4 CLINICAL TRIAL (2018) (0)
PNR-30EFFECTIVITY OF TWO DIFFERENT RADIATION-AVOIDING TREATMENT REGIMENS FOR YOUNG CHILDREN WITH PINEOBLASTOMA—RESULTS OF THE HIT2000 TRIAL (2016) (0)
Supratentorial CNS-PNETs in children; a Swedish population-based study with molecular re-evaluation and long-term follow-up (2023) (0)
OS02.1 Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medulloblastoma - the NOA-07 trial (2017) (0)
HG-27ACUTE TOXICITY OF TEMOZOLOMIDE- VERSUS CISPLATIN-BASED RADIOCHEMOTHERAPY IN PEDIATRIC HIGH GRADE GLIOMA: COMPARATIVE ANALYSIS OF PROSPECTIVE, CONSECUTIVE, MULTICENTRIC AND MULTINATIONAL TRIALS OF THE GERMAN HIT-HGG STUDY GROUP (2016) (0)
HG-75CLINICAL, RADIOLOGICAL, AND HISTO-GENETIC CHARACTERISTICS OF LONG-TERM SURVIVORS OF DIFFUSE INTRINSIC PONTINE GLIOMA: A COLLABORATIVE REPORT FROM THE INTERNATIONAL AND SIOP-E DIPG REGISTRIES (2016) (0)
Randomized multicenter trial on patients wit childhood craniopharyngioma (KRANIOPHARYNGEOM 2007) – Update after 12 months of recruitment (2008) (0)
GC-02CNS GERMINOMAS ARE CHARACTERIZED BY GLOBAL DEMETHYLATION, CHROMOSOMAL INSTABILITY AND MUTATIONAL ACTIVATION OF THE KIT-, RAS/RAF/ERK- AND AKT-PATHWAYS (2015) (0)
Molecular Neuropathology and 49th Annual Meeting of the German Society of Neuropathology and Neuroanatomy (2004) (0)
EMBR-12. IMPROVED DIAGNOSTIC ALGORITHM FOR DIFFERENTIAL DIAGNOSTICS OF CNS EMBRYONAL TUMORS (FORMER CNS-PNET) BY NEUROPATHOLOGICAL RE-EVALUATION OF 256 CASES AND CROSSVALIDATION BY METHYLATION CLASSIFICATION (2018) (0)
Mutated SON putatively causes a cancer syndrome comprising high-risk medulloblastoma combined with café-au-lait spots (2019) (0)
RANK (TNFRSF11A )I s Epigenetically Inactivated and Induces Apoptosis (2012) (0)
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma (2022) (0)
The KidsCancerKinome: Validation of Cell Cycle Genes as Potential Drug Targets in Pediatric Tumors (2011) (0)
Cancer Therapy : Preclinical Anticancer Effects of Niclosamide in Human Glioblastoma (2013) (0)
Abstract 3425: Expression and functional role of erbB2 in human hepatoblastoma (2010) (0)
Neuropathology and molecular diagnosis of brain tumors. Where are we in 2015? An international survey on diagnostic practices (2016) (0)
EPEN-27. CDKN2A DELETION IN SUPRATENTORIAL EPENDYMOMA WITH RELA ALTERATION INDICATES A DISMAL PROGNOSIS – A RETROSPECTIVE ANALYSIS OF THE HIT EPENDYMOMA TRIAL COHORT (2020) (0)
Correlation of the c-kit mutational status of gastrointestinal stromal tumors with the clinical response to the tyrosine kinase inhibitor imatinib (2004) (0)
LG-01. MULTI-FOCAL OR DISSEMINATED LOW GRADE GLIOMA IN CHILDREN: THE RILEY HOSPITAL FOR CHILDREN EXPERIENCE (2012) (0)
RO-23RECURRENT EPENDYMOMA A CHALLENGING THERAPY: RE-IRRADIATION PROLONGS SURVIVAL IN FAILURE OF RADICAL RESECTION (2016) (0)
MBCL-11. CONCURRENT IDH1 AND SMARCB1 MUTATIONS IN A PEDIATRIC MEDULLOBLASTOMA: A CASE REPORT (2018) (0)
Pseudoprogression is frequent following front-line radiotherapy in pediatric low-grade glioma - results from the German LGG cohort. (2021) (0)
CLIN-PEDIATRICS CLINICAL RESEARCH (2012) (0)
Abstract C116: The KidsCancerKinome: Validation of drug targets for high risk childhood cancers (2009) (0)
GE-25NEXT GENERATION COPY NUMBER ANALYSIS BY MOLECULAR INVERSION PROFILING - A HELPFUL TOOL IN DIAGNOSTICS AND PROGNOSTIFICATION OF TUMORS OF THE CNS. (2014) (0)
EPEN-09. IMPACT OF MOLECULAR SUBGROUP ON OUTCOME FOR INFANTS <12 MONTHS WITH INTRACRANIAL EPENDYMOMA - GERMAN EXPERIENCE FROM HIT2000, INTERIM-2000-REGISTRY AND I-HIT-MED REGISTRY (2020) (0)
Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors (2019) (0)
JS04.4.A Beyond β-catenin: Genetic alterations ofTP53 andOTX2 and older age indicate increased risk of relapse in WNT medulloblastomas (2022) (0)
Abstract LB-514: Contribution of ADAM17 to Kit ligand ectodomain shedding in high-grade gliomas (2012) (0)
Shift towards less radical, hypothalamus-sparing treatment strategies in childhood craniopharyngioma – Comparison between patients recruited in KRANIOPHARYNGEOM 2000 and 2007 (2014) (0)
Abstract 4351: A mammalian mitochondrial ribosomal protein contributes to intrinsic and extrinsic pathways for apoptosis in high grade gliomas of childhood (2010) (0)
MEDB-51. Impact of residual tumor on outcomes in children and adolescents with medulloblastoma in the German HIT-cohort (2022) (0)
4100 ORAL Radiation Therapy in Childhood Low Grade Glioma (LGG) – a Subgroup Analysis Within the Scope of the German Multicenter Treatment Study HIT-LGG 1996 (2011) (0)
BIOM-59. TERT PROMOTER MUTATION AND MGMT PROMOTER METHYLATION-MEDIATED SENSITIVITY TO TEMOZOLOMIDE IN IDH-WILDTYPE GLIOBLASTOMA: IS THERE A LINK? (2020) (0)
Frontal cystic lesion with a contrast-enhancing mural nodule: Question (2017) (0)
RARE-10. MULTICENTER PILOT STUDY OF RADIO-CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR ADULTS WITH MEDULLOBLASTOMA – THE NOA-07 TRIAL. (2017) (0)
8 INVITED KidsCancerKinome; Looking for new targets in paediatric cancers (2007) (0)
EPN-20NEWLY DIAGNOSED METASTATIC INTRACRANIAL EPENDYMOMA IN CHILDREN: FREQUENCY, TREATMENT AND OUTCOME IN THE POPULATION BASED, PROSPECTIVE HIT-SERIES. (2016) (0)
HG-34HIGH-GRADE GLIOMA ARISING IN SURVIVORS OF PEDIATRIC ACUTE LYMPHOBLASTIC MALIGNANCIES: A COOPERATIVE ANALYSIS OF THE GERMAN HIT-HGG/-GBM AND ALL-BFM/COALL STUDIES (2016) (0)
Catenin Gene β Degradation Targeting Box of the Childhood Hepatoblastomas Frequently Carry a Mutated Updated (1999) (0)
Abstract C114: The KidsCancerKinome: Validation of CDK2 as potential drug target in pediatric tumors (2009) (0)
MHH-NB11, A new neuroblastoma cell line (1989) (0)
EPEN-06. CHEMOTHERAPY OF RECURRENT EPENDYMOMA: LONG-TERM RESPONSE ONLY IN FEW CASES (2020) (0)
MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT/non-SHH medulloblastoma despite highly intensified chemotherapy – Results of the MET-HIT2000-BIS4 trial (2022) (0)
Abstract 196: Functional role of death-associated protein 3 in high grade gliomas of childhood (2011) (0)
MEDB-35. Relationship between genetic profile, histology, clinical features and long-term outcome in young children medulloblastoma (YCMB) treated with upfront high dose chemotherapy (HDCT) in Italy (2022) (0)
HGG-21. Oncogenic tyrosine kinase gene fusions in infant-type hemispheric gliomas - comparison of RNA- and DNA-based methods for their reliable detection (2022) (0)
Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification (2023) (0)
LGG-15. REQUIREMENT OF ADJUVANT TREATMENT IN CHILDHOOD LOW GRADE GLIOMAS (LGG) OF THE SPINAL CORD: EXPERIENCES FROM THE GERMAN LGG STUDY GROUP (2018) (0)
Mutations of BRAF in low-grade Astrocytomas (2008) (0)
GCT-29. DOES TUMOUR MARKER DECLINE PREDICT OUTCOME IN INTRACRANIAL NON-GERMINOMATOUS GERM CELL TUMOURS (NGGCTs)? (2020) (0)
Extensive genomic demethylation - a histological hallmark of germinomatous tumors (2006) (0)
MEDB-17. Re-irradiation for recurrent medulloblastoma in a matched cohort: Advantageous especially in patients without resection (2022) (0)
Microarray analysis of differential methylation during glioma progression (2004) (0)
Correlation of conventional magnetic resonance imaging features with O6-methylguanine-DNA-methyltransferase gene promoter methylation status and survival outcomes in patients with newly diagnosed glioblastoma: Single-center correlative imaging substudy from a prospective clinical trial (2018) (0)
Erratum: SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma (Klinische Padiatrie (2019) 231 (107-135) DOI: 10.1055/a-0889-8256) (2019) (0)
PATH-32. GENOMIC LANDSCAPE AND BIOLOGY OF MEDULLOBLASTOMA IN ADULTS (2019) (0)
MEDB-71. Molecular characterisation of group 4 medulloblastoma improves risk-stratification and its biological understanding (2022) (0)
IMMU-28. DECIPHERING THE AT/RT LIGANDOME (2018) (0)
MBCL-11. TIME TO RADIOTHERAPY IMPACTS SURVIVAL IN PEDIATRIC AND ADOLESCENT NON-METASTATIC MEDULLOBLASTOMA TREATED BY UPFRONT RADIOTHERAPY – A REPORT FROM THE HIT 2000 TRIAL (2020) (0)
Abstract LB-324: A whole chromosome aberration phenotype in non-WNT/non-SHH tumors predicts outcome within standard-risk medulloblastomas from the HIT-SIOP-PNET4 clinical trial (2018) (0)
MOLECULAR GENETIC DETERMINANTS OF LONG-TERM SURVIVAL WITH GLIOBLASTOMA (2014) (0)
Methylation class oligosarcoma may encompass IDH-wildtype gliomas (2022) (0)
BIOM-08. DNA METHYLATION-BASED SUBGROUPING PREDICTS SURVIVAL BENEFIT FROM LOMUSTINE/TEMOZOLOMID COMBINATION THERAPY IN MGMT PROMOTOR-METHYLATED GLIOBLASTOMA (2021) (0)
Abstract LB-216: Frequent oncogenic tyrosine kinase gene fusions in supratentorial glioblastomas of young children (2020) (0)
MBCL-45. ROLE OF IRRADIATION IN RELAPSED MEDULLOBLASTOMA: A REPORT OF THE GERMAN MEDULLOBLASTOMA RELAPSE STUDIES (2018) (0)
Frontal cystic lesion with a contrast-enhancing mural nodule: Answer (2017) (0)
Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma. (2018) (0)
Abstract 4348: PDGF-Rα expression and activation of the MAPK pathway in disseminated pilocytic astrocytomas (2010) (0)
2.O.07 KIDSCANCERKINOME; KINASE DRUG TARGETS IN PAEDIATRIC CANCERS (2010) (0)
Short communication Allelic loss at 10q23.3 but lack of mutation of PTEN/MMAC1 in chromophobe renal cell carcinoma (2001) (0)
Molecular pathological insights reveal a high number of unfavorable risk patients among children treated for medulloblastoma and CNS‐PNET in Oslo 2005–2017 (2022) (0)
Low grade glioma in pediatric NF-1 patients (2008) (0)
Abstract 3561: Recurrent genetic alterations in epigenetic pineoblastoma subtypes (2023) (0)
Abstract 2492: Identification of RBMS1 in the amplified region 2q24 as a major driver of cellular growth in childhood hepatoblastoma (2022) (0)
Abstract 2588: Targeting overexpressed PLK1 and Aurora kinases in childhood medulloblastoma (2011) (0)
Effects of Granulocyte Colony-Stimulating Factor in Children with Severe Cnngenital Neutropenia * (2005) (0)
HGG-28. ONCOGENIC TYROSINE KINASE GENE FUSIONS IN SUPRATENTORIAL HIGH GRADE GLIOMAS OF YOUNG CHILDREN - COMPARISON OF RNA- AND DNA-BASED METHODS FOR THEIR RELIABLE DETECTION (2021) (0)
GENE-13. PEDIATRIC MENINGIOMAS ARE CHARACTERIZED BY DISTINCT METHYLATION PROFILES DIFFERENT FROM ADULT MENINGIOMAS (2018) (0)
LGG-14. PEDIATRIC DIFFUSE GLIOMA WHO-GRADE II: PROGNOSTIC IMPACT OF MOLECULAR GENETIC VARIANTS (2018) (0)
The molecular landscape of ETMR at diagnosis and relapse (2019) (0)
EPEN-36. THE TREATMENT OUTCOME OF PAEDIATRIC SUPRATENTORIAL C11ORF95-RELA FUSED EPENDYMOMA: A COMBINED REPORT FROM E-HIT SERIES AND AUSTRALIAN NEW ZEALAND CHILDREN’S HAEMATOLOGY/ONCOLOGY GROUP (2020) (0)
Identification of genetic alterations in pediatric hepatocellular carcinomas (2014) (0)
MBCL-06. RISK STRATIFICATION IMPROVEMENT OF THE HIT2000 AND I-HIT-MED COHORTS USING MOLECULAR SUBTYPES I-VIII OF GROUP 3/4 MEDULLOBLASTOMAS (2020) (0)
H3F3A-G34R mutant high grade neuroepithelial neoplasms with glial and dysplastic ganglion cell components (2019) (0)
QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL (2020) (0)
PATH-27. GIANT CELL GLIOBLASTOMA DOES NOT REPRESENT A DISTINCT TUMOUR ENTITY BUT STRATIFIES INTO DIFFERENT GENETICALLY DEFINED SUBTYPES (2019) (0)
QOS-26HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN HIT-SIOP-PNET4 TRIAL SURVIVORS: DIFFERENCES BETWEEN MEDULLOBLASTOMA MOLECULAR SUBGROUPS (2016) (0)
Em-24. Telomerase Inhibition Induces Growth Arrest in Paediatric Ependymoma (2012) (0)
A Matched-pair Analysis on the Effect of Migration Background on Response Rates and Survival of Cancer Patients Treated at a Comprehensive Cancer Center in Germany (2020) (0)
Childhood Craniopharyngioma: Changes of Treatment Strategies in Multinational Trials During the Last 12 Years (2014) (0)
MEDB-41. Identifying a subgroup of patients with early childhood sonic hedgehog-activated medulloblastoma with unfavorable prognosis after treatment with radiation-sparing regimens including intraventricular methotrexate (2022) (0)
Abstract 4797: A member of the SLC25 family is epigenetically inactivated in human gliomas and suppresses cell growthin vitro (2011) (0)
MB-24 Routine diagnostic medulloblastoma subgrouping using low-cost, low-input DNA methylomics: Application to trials cohorts previously refractory-to-analysis [conference abstract] (2016) (0)
MB-28GENOME-WIDE COPY NUMBER ANALYSIS, NEUROPATHOLOGICAL CLASSIFICATION AND ANALYSIS OF HEDGEHOG ACTIVATION: HISTOLOGY REFLECTS GENETICS AND BIOLOGY IN MEDULLOBLASTOMAS OF YOUNG CHILDREN (2015) (0)
c-Kit gene mutations in intracranial germ cell tumors (2010) (0)
HGG-49. Gliomatosis cerebri in children: A collaborative report from the European Society for Pediatric Oncology (SIOPE) (2022) (0)
Childhood Craniopharyngioma – Changes of treatment strategies in the multinational prospective trials KRANIOPHARYNGEOM 2000/2007 (2013) (0)
Early wound site seeding in a patient with CNS high-grade neuroepithelial tumor with BCOR alteration : A case report Running title : Wound site seeding in CNS HGNET-BCOR tumor (2019) (0)
MEDB-16. Persistent radiological lesions at the end of primary therapy in childhood medulloblastoma: residual lesion or active residual tumor? (2022) (0)
PATH-11. PROSPECTIVE (EPI-)GENETIC CLASSIFICATION OF > 1,000 PEDIATRIC CNS TUMORS—THE MNP 2.0 STUDY (2020) (0)
EPEN-19. Impact of molecular classification on prognosis in children and adolescents with spinal ependymoma: Results from the HIT-MED database (2022) (0)
HGG-24. MOLECULAR, PATHOLOGICAL, RADIOLOGICAL AND IMMUNE PROFILING OF NON-BRAINSTEM PAEDIATRIC HIGH GRADE GLIOMA FROM THE HERBY PHASE II RANDOMISED TRIAL (2018) (0)
Abstracts of the 52nd Workshop for Pediatric Research (2017) (0)
MBCL-29. FEASIBILITY OF SCREENING AND REASONS FOR SCREENING FAILURES IN THE SIOPE PNET 5 MB TRIAL (2018) (0)
WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma (2014) (0)
EPID-18. NOONAN SYNDROME CAN BE ASSOCIATED WITH HIGH GRADE GLIOMA; A REPORT OF TWO CASES (2017) (0)
P45: Comprehensive genomic analysis of desmoplastic medulloblastomas reveals novel amplified genes and supports a monoclonal origin of the different histologic components (2005) (0)
PNR-32UPDATE OF DIAGNOSTICS OF PRIMITIVE NEUROECTODERMAL TUMOURS OF THE CNS - NEUROPATHOLOGICAL RE-EVALUATION OF 99 CASES (2016) (0)
Abstract C115: The KidsCancerKinome: Validation of Aurora kinases as potential drug targets in pediatric tumors (2009) (0)
Correction: SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma (2019) (0)
An 11 Year Old Child with a Right Parieto‐Occipital Lesion (2015) (0)
TMIC-47. IMMUNOBIOLOGICAL CHARACTERIZATION OF CNS GERMINOMAS – EVIDENCE FOR INFLAMMATORY AND SUPPRESSIVE IMMUNOLOGICAL MECHANISMS (2017) (0)
Spinal glioneuronal tumors: location matters!-Reply. (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Torsten Pietsch?

Torsten Pietsch is affiliated with the following schools:

Medical University of Vienna
McGill University
University of Colorado Denver
Hannover Medical School
University of Tübingen
University of Bern
University of Bonn

Torsten Pietsch's Academic­Influence.com Rankings

Why Is Torsten Pietsch Influential?

Torsten Pietsch's Published Works

Published Works

What Schools Are Affiliated With Torsten Pietsch?

Torsten Pietsch's AcademicInfluence.com Rankings